# Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

> **NCT06851806** · NA · RECRUITING · sponsor: **AstraZeneca** · enrollment: 138 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **DRUG:** Palivizumab 15 mg/kg

## Key facts

- **NCT ID:** NCT06851806
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851806, "Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06851806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*